Document:

<PAGE>

EXHIBIT 10.3  Severance Agreement between Bentley Communications Corp. and
              Gordon F. Lee

                               SEVERANCE AGREEMENT

This Severance Agreement ("Agreement") is entered to be effective as of October
10, 2002 by and between Bentley Communications Corp., a Florida corporation
("Bentley"), and Gordon F. Lee, a person residing in the State of California
("Lee").

                                   [Recitals]

WHEREAS, Lee has personally guaranteed certain debts for legal fees for Bentley;

WHEREAS, Lee, subject to the terms and conditions of this Agreement, has agreed
to terminate all employment, consulting and loan agreements with Bentley; and

WHEREAS, Lee, subject to the terms and conditions of this Agreement, is
resigning the offices of Chief Executive Officer, Chief Financial Officer, and
Secretary of Bentley to focus more time on other interests.

WHEREAS, Lee, subject to the terms and conditions of this Agreement, has agreed
to serve as a Director of Bentley until any and all Bentley obligations that
were personally guaranteed by Lee have been fully satisfied.

                                 [The Agreement]

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is acknowledged, Bentley and Lee agree as follows.

1. Bentley shall indemnify Lee to the fullest extent permitted by law if Lee is
or becomes a party to or witness or other participant in, or is threatened to be
made a party to or witness or other participant in, any threatened, pending or
completed action, suit, proceeding or alternative dispute resolution mechanism,
whether civil, criminal, administrative, investigative or other (hereinafter a
"CLAIM") by reason of (or arising in part out of) any event or occurrence
related to the fact that Lee personally guaranteed any of Bentley's obligations,
is or was a director, officer, employee, agent or fiduciary of Bentley, against
any and all expenses (including attorneys' fees and all other costs, expenses
and obligations incurred in connection with investigating, defending, being a
witness in or participating in (including on appeal), or preparing to defend, be
a witness in or participate in, any such action, suit, proceeding, alternative
dispute resolution mechanism, hearing, inquiry or investigation), judgments,
fines, penalties and amounts paid in settlement (if such settlement is approved
in advance by Bentley, which approval shall not be unreasonably withheld) of
such Claim and any federal, state, local or foreign taxes imposed on Lee as a
result of the actual or deemed receipt of any payments under this Agreement
(collectively, hereinafter "EXPENSES"), including all interest, assessments and
other charges paid or payable in connection with or in respect of such Expenses.
Such payment of Expenses shall be made by Bentley as soon as practicable but in
any event no later than twenty days after written demand by Lee is presented to
Bentley.

<PAGE>

2. Bentley shall immediately issue Lee Five Million (5,000,000) restricted
shares of its $.0001 par value common stock in consideration for Lee's
termination of all employment and consulting agreements with Bentley.
Furthermore, Bentley represents and warrants that the newly issued shares shall
be fully paid non-assessable shares of common stock of Bentley. Moreover,
Bentley approves, ratifies and confirms the status of Lee's 42,900,000 shares of
Bentley common stock (the 5,000,000 new shares to be issued per this paragraph,
plus 37,900,000 currently held by Lee) as fully paid non-assessable shares of
common stock. Bentley shall fully cooperate with Lee in any subsequent sale or
transfer of Lee's shares, including but not limited to payment by Bentley of any
transfer agent fees and legal opinions.

3. Subject to the terms and conditions of this Agreement, Lee resigns, effective
immediately, as Chief Executive Officer, Chief Financial Officer and Secretary
of Bentley. Lee's resignation is not because of any disagreement with Bentley
concering Bentley's operations, policies or practices, but so that Lee can focus
on other activities.

4. This Agreement may be executed in one or more counterparts, each of which
shall constitute an original.

5. This Agreement shall be binding upon and inure to the benefit of and be
enforceable by the parties hereto and their respective successors, assigns,
including any direct or indirect successor by purchase, merger, consolidation or
otherwise to all or substantially all of the business and/or assets of Bentley.
Bentley shall require and cause any successor (whether direct or indirect by
purchase, merger, consolidation or otherwise) to all, substantially all, or a
substantial part, of the business and/or assets of Bentley, by written agreement
in form and substance satisfactory to Lee, expressly to assume and agree to
perform this Agreement in the same manner and to the same extent that Bentley
would be required to perform if no such succession had taken place. This
Agreement shall continue in effect with respect to Claims relating to
Indemnifiable Events regardless of whether Lee continues to serve as a director,
officer, employee, agent or fiduciary of Bentley or of any other enterprise at
Bentley's request.

6. In the event that any action is instituted by Lee under this Agreement or
under any liability insurance policies maintained by Bentley to enforce or
interpret any of the terms hereof or thereof, Lee shall be entitled to be paid
all Expenses incurred by Lee with respect to such action, regardless of whether
Lee is ultimately successful in such action, and shall be entitled to the
advancement of Expenses with respect to such action, unless, as a part of such
action, a court of competent jurisdiction over such action determines that each
of the material assertions made by Lee as a basis for such action was not made
in good faith or was frivolous. In the event of an action instituted by or in
the name of Bentley under this Agreement to enforce or interpret any of the
terms of this Agreement, Lee shall be entitled to be paid all Expenses incurred
by Lee in defense of such action (including costs and expenses incurred with
respect to Lee's counterclaims and cross-claims made in such action), and shall
be entitled to the advancement of Expenses with respect to such action, unless,
as a part of such action, a court having jurisdiction over such action
determines that each of Lee's material defenses to such action was made in bad
faith or was frivolous.

<PAGE>

7. All notices and other communications required or permitted hereunder shall be
in writing, shall be effective when given, and shall in any event be deemed to
be given (a) five (5) days after deposit with the U.S. Postal Service or other
applicable postal service, if delivered by first class mail, postage prepaid,
(b) upon delivery, if delivered by hand, (c) one business day after the business
day of deposit with Federal Express or similar overnight courier, freight
prepaid, or (d) one day after the business day of delivery by facsimile
transmission, if delivered by facsimile transmission, with copy by first class
mail, postage prepaid.

8. Consent to Jurisdiction. Bentley and Lee each hereby irrevocably consent to
the jurisdiction of the courts of the State of California for all purposes in
connection with any action or proceeding which arises out of or relates to this
Agreement and agree that any action instituted under this Agreement shall be
commenced, prosecuted and continued only in the State of California in and for
Los Angles County, which shall be the exclusive and only proper forum for
adjudicating such a claim.

9. The provisions of this Agreement shall be severable in the event that any of
the provisions hereof (including any provision within a single section,
paragraph or sentence) are held by a court of competent jurisdiction to be
invalid, void or otherwise unenforceable, and the remaining provisions shall
remain enforceable to the fullest extent permitted by law. Furthermore, to the
fullest extent possible, the provisions of this Agreement (including, without
limitations, each portion of this Agreement containing any provision held to be
invalid, void or otherwise unenforceable, that is not itself invalid, void or
unenforceable) shall be construed so as to give effect to the intent manifested
by the provision held invalid, illegal or unenforceable.

10. This Agreement shall be governed by and its provisions construed and
enforced in accordance with the laws of the State of California, as applied to
contracts between California residents, entered into and to be performed
entirely within the State of California, without regard to the conflict of laws
principles thereof.

11. No amendment, modification, termination or cancellation of this Agreement
shall be effective unless it is in writing signed by both the parties hereto. No
waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provisions hereof (whether or not similar) nor
shall such waiver constitute a continuing waiver.

12. This Agreement sets forth the entire understanding between the parties
hereto and supersedes and merges all previous written and oral negotiations,
commitments, understandings and agreements relating to the subject matter hereof
between the parties hereto.

13. Nothing contained in this Agreement shall be construed as giving Lee any
right to be retained in the employ of Bentley or any of its subsidiaries.

<PAGE>

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first above written.

                                           Gordon F. Lee

                                           By: ________________________
                                           Name: Gordon F. Lee

                                           Bentley Communications Corp.

                                           By: ________________________
                                           Name: Harry Hargens
                                           Title: PresidentASSET PURCHASE AGREEMENT

  
 Portions of this exhibit marked [*] are omitted and 
 are requested to be treated confidentially. 
  
 Exhibit 10.91 
  
 ASSET PURCHASE AGREEMENT 
  
 THIS ASSET PURCHASE AGREEMENT is executed as of the 21st day of October, 2002, by and between, VESTA THERAPEUTICS, Inc., a Delaware
corporation with its headquarters at 7600 Wisconsin Avenue, Bethesda, MD 20814 (“VESTA”), and INCARA CELL TECHNOLOGIES, INC., a Delaware corporation with its headquarters at 79 T. W. Alexander Drive 4401Research Commons, Suite 200,
Research Triangle Park, North Carolina 27709 (“ICT”).  
  
  
 ARTICLE I—DEFINITIONS 
  
 The following terms as used in this Agreement shall have the
meanings set forth below: 
  
 SECTION 1.1  “Acquired Assets” means all the assets,
properties, and business of ICT of every kind, character, and description, whether tangible, intangible, real, personal, or mixed, and wherever located to the extent they are related or useful for Cell Therapy and all Recorded Information and
Regulatory Information related thereto (all of which are sometimes collectively referred to as the Assets), but excluding cash and accounts receivable. 
  
 SECTION 1.2  “Affiliate” means, as to any Person: (i) any other Person of which more than fifty percent (50%) of the voting stock or other equity interest is owned,
directly or indirectly, by such Person; (ii) any other Person that, directly or indirectly, owns more than fifty percent (50%) of the voting stock or other equity interest of such Person; or (iii) any other Person under the direct or indirect
control of a Person described in clause (i) or clause (ii). 
  
 SECTION
1.3  “Agreement” means this Asset Purchase Agreement, as may be amended from time to time, including all Schedules hereto. 
  
 SECTION 1.4  “Assumed Liabilities” means all obligations of ICT under the Contracts that accrue for, or are attributable to, periods after the Closing Date.

  
 SECTION 1.5  “Cell Therapy” means biological cells, products of said cells,
and/or the use of said cells, including without limitation cells which have been isolated, contacted or otherwise manipulated to any extent in vitro, in research, diagnosis or therapy. 
  

SECTION 1.6  “Closing Date” means the date on which the “Closing” (as defined in Section 3.1) occurs. 

 
 SECTION 1.7  “Contracts” means only those agreements expressly listed on Schedule 4.8.

  
 SECTION 1.8  “Documentation” means all records, asset ledgers, books of
account, inventory records, customer and supplier lists, sales literature and advertising and promotional materials relating to the Product or any of the Acquired Assets. 

  
 SECTION 1.9  “Excluded Assets” means all
assets, properties, rights and interests of ICT other than the Acquired Assets. 
  
 SECTION
1.10  “Excluded Liabilities” means all liabilities, obligations, commitments and debts of ICT that are not Assumed Liabilities. Without limiting the generality of the foregoing and by way of example only, all liabilities,
obligations, commitments or debts: (i) under the Contracts that accrue for, or are attributable to, periods prior to the Closing Date; (ii) related to the Acquired Assets and incurred prior to, or attributable to periods occurring prior to, the
Closing Date; or (iii) arising out of the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of the Product on or prior to the Closing Date are Excluded Liabilities.

  
 SECTION 1.11  “FDA” means the United States Food and Drug Administration.

  
 SECTION 1.12  “IND” means the Investigational New Drug Application (reference
no. BB-IND 10538) filed with the FDA, together with any supplements thereto, and all legal rights and privileges belonging or accruing to the owner or holder thereof. 
  
 SECTION 1.13  “Intellectual Property” means all of the intellectual properties and property rights that are owned, leased or licensed by
ICT as of the Closing Date and used in, useful for, or related to the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of Cell Therapy, including without limitation: (i)
Know-How; and (ii) the United States and foreign patents and applications for patent relating thereto listed on Schedule 4.10 (together with all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals or
extensions thereof and all SPCs with respect thereto, the “Patents”). 
  
 SECTION
1.14  “Inventory” means all supplies and quantities of ICT as of the Closing Date wherever located, of: (i) human and animal cells and tissues; and, (ii) the materials and supplies to be used or consumed in the research or
production of Cell Therapy compositions or methods, but excluding furniture fixtures and equipment not included within the Transamerica Note. 
  
 SECTION 1.15  “Know-how” means any and all confidential or generally unavailable technical information and know-how which relates to or is useful for Cell Therapy and
is in the possession of ICT as of the Closing Date, including, without limitation, biological, chemical, pharmacological, toxicological, clinical, assay, control, sales and manufacturing protocols, data or any other information. 

 
 SECTION 1.16  “Liens” means mortgages, liens, pledges, charges, security interests,
obligations relating to, or encumbrances of any kind whatsoever, but excluding purchase money security interests on assets securing the Transamerica Note and the assets under the August 12, 2002 agreement between ICT and Miltenyi Biotec, Inc

  
 SECTION 1.17  “NDA” means an application(s) filed with the FDA for marketing
authorization of the Cell Therapy Products within the United States. 

 
 2 

  
 SECTION 1.18  “Net Sales” shall mean
the gross amount billed or invoiced by VESTA or an Affiliate of VESTA for sale or other disposition of Products, less the following deductions all with respect to Product: (a) discounts, chargebacks, allowances for bad debts or uncollectible
amounts, Medicaid/Medicare rebates (other than as described in (d) below) and allowances actually taken; (b) sales, use, value added and excise taxes, import and customs duties, tariffs, and any other similar taxes, duties or tariffs, to the extent
actually paid by the selling party; (c) freight, insurance, packaging costs and other transportation charges to the extent added to the sales price; and (d) amounts repaid or credits taken by reason of rejections, defects or returns or because of
retroactive price reductions or due to recalls or government laws or regulations requiring rebates. “Net Sales” shall not include amounts for any Product furnished to a third party for which payment is not intended to be received,
including, but not limited to, Products used in clinical trials and Products distributed as promotional and free goods. Furthermore, “Net Sales” shall not include amounts from sales or other dispositions of Products between VESTA
and any of its Affiliates. 
  
 SECTION 1.19  “Person” means an individual, a
corporation, a partnership, a limited liability company, an association, a trust, or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. 
  
 SECTION 1.20  “Product” means any product or composition useful for the research, diagnosis or
treatment of disease or injury to the extent said Product is covered by a Valid Claim. 
  
 SECTION
1.21  “Recorded Information” means information or data that is physically recorded or stored in readable or retrievable form (e.g., writing, microfiche, computer disk, etc.). 
  

SECTION 1.22  “Regulatory Documentation” means all regulatory filings, submissions, notices (of approval and otherwise),
correspondence and supporting materials and safety data for the Product owned by ICT or to which ICT has rights as of the Closing Date, including without limitation (i) the IND and all approvals thereof, all of which in existence as of the date
hereof and as of the Closing Date are set forth on Schedule 1.22, and (ii) all clinical data contained or related to any of the foregoing, and all legal rights and privileges belonging or accruing to the owner or holder thereof. 

 
 SECTION 1.23  “Required Notice” means notification to the FDA of the transfer of the IND.

  
 SECTION 1.24  “SPC” means a right based upon a patent to exclude others from
making, using or selling the Product, such as a Supplementary Protection Certificate. 
  
 SECTION
1.25  “Specified Consents” means the written consents of those Persons set forth on Schedule 4.1 to the sale, transfer, assignment and conveyance of the Acquired Assets to VESTA. 
  
 SECTION 1.26  “Technical Package” means Recorded Information relating to the manufacture and sale of
Product by ICT, and on account of or for ICT by Third Party(s), prior to the date of this Agreement, which shall contain such items, without limitation, as starting 

 
 3 

 
material specifications, finished product specifications, assays, standard operating procedures and batch production records. 
  
 SECTION 1.27  “Third Party” means any Person other than a party to this Agreement or an Affiliate of either party. 

 
 SECTION 1.28  “Transamerica Note” means the promissory note dated October 31, 2001 in the
original principal amount of $499,254.73, issued by ICT and its Affiliates to Transamerica Technology Finance Corporation. 
  
 SECTION 1.29  “Valid Claim” shall mean (a) any claim of an issued and unexpired patent within the Acquired Assets on the Closing Date which has not been held unenforceable or invalid by a court or
other governmental agency of competent jurisdiction in an unappealed or unappealable decision, and which has not been disclaimed or admitted to be invalid or unenforceable through reissue or otherwise, or (b) on the Closing Date and with respect to
the jurisdiction in question, a pending claim in a pending patent application within the Acquired Assets. Notwithstanding Section 1.29(b) above, in the event that a pending claim in a pending patent application does not issue as a valid and
enforceable claim in an issued patent within five (5) years after the date from which such patent application takes earliest priority, such a pending claim shall not be a Valid Claim, unless and until such pending claim subsequently issues as a
valid and enforceable claim in an issued patent, in which case such claim shall be reinstated and be deemed to be a Valid Claim as of the date of issuance of such patent. 
  
  
 ARTICLE II—PURCHASE AND SALE 
  
 SECTION 2.1  Purchase and Sale.    Subject to the terms and conditions set forth in this Agreement, ICT agrees to sell, convey, assign and transfer
to VESTA, and VESTA agrees to purchase, on the Closing Date, all of the Acquired Assets. ICT shall retain the Excluded Assets. 
  
 SECTION 2.2  Assumption of Liabilities.    Subject to the terms and conditions of this Agreement, VESTA agrees to assume, on the Closing Date, the Assumed Liabilities. ICT expressly
understands and agrees that VESTA does not assume, and shall not be liable for, any Excluded Liabilities and that ICT shall retain all Excluded Liabilities. 
  
 SECTION 2.3  Purchase Price. 
  
 (a)  VESTA shall pay, in consideration for the Acquired Assets, the following amounts: 
  
 (i)  on the Closing Date, the sum of Three Million Dollars ($3,000,000) to ICT; and 
  
 (ii)  additional compensation pursuant to Section 2.4. 
  
 (b)  The payment in
Section 2.3(a)(i) will be tendered by VESTA to ICT by Federal wire of funds to First Union National Bank, ABA routing # 053000219, and designated “For credit to the account of Incara Cell Technologies, Inc. Account # 4002844483. 

 

 
 4 

  
 SECTION 2.4  Additional Compensation.

  
 (a)  VESTA shall make quarterly payments to ICT equal to [*] percent ([*]%) of Net Sales
by VESTA of Products in each reporting period. 
  
 (b)  VESTA shall pay any amounts due and payable on Net
Sales within forty-five (45) days after the end of the reporting period in which such Net Sales were billed or invoiced by VESTA. 
  
 (c)  VESTA’s payment obligations under Section 2.4(a) above will cease with respect to any payment that otherwise would result from the sale of a Product that occurs after the date of expiration or final
determination of invalidity of the last Valid Claim that covers the making, using, offering for sale, selling or importing of such Product. 
  
 (d)  ICT and VESTA recognize and agree that, in order to develop and commercialize Products, it will be necessary for VESTA to make use of and/or incorporate multiple elements of intellectual
property from multiple sources. VESTA shall determine, in its sole judgment, which elements of intellectual property are necessary and/or desirable for the development and/or commercialization of the licensed technology. Royalty payments or license
fees to third parties may occur if intellectual property owned by a third party is required or desirable for the commercialization of the Licensed Technology. All types of payments to third parties that VESTA has determined and/or may determine are
necessary or desirable to obtain licenses or other rights to use or incorporate other intellectual property or products relating to development and commercialization of Products, shall be creditable against amounts otherwise owed to ICT hereunder;
provided, that in no one year shall such expenses be credited against more than sixty-seven percent (67%) of payments otherwise owed to ICT. Any greater amount of such expenses may be carried over and credited against amounts owed in future years.

  
 (e)  No additional compensation shall be payable with respect to any sale or other transfer of a
Product between VESTA and its Affiliates. Such additional compensation shall instead accrue only upon the first sale of such Product to a third party that is not an Affiliate of VESTA. 
  
 (f)  If VESTA sells a Product in combination with another product or products where one or more of such products are not Products (a “Combination
Product”), Net Sales under such circumstances shall be calculated by multiplying the Net Sales of the Combination Product (as defined in the standard Net Sales definition) by the fraction, A/(A + B) where A is the average sale price of the
Product when sold separately in finished form and B is the average sale price of the other product(s) sold separately in finished form. In the event that the average sale price of the Product can be determined but the average sale price of the other
product(s) in the Combination Product cannot be determined, Net Sales for purposes of determining payments shall be calculated by multiplying the Net Sales of the Combination Products by the fraction C/(C + D) where C is VESTA’s average sales
price of the Product and D is the difference between the average selling price of the Combination Product and the average selling price of the Product. If the average sale price of the other product(s) in the Combination Product can be determined
but the average price of the Product cannot be determined, Net Sales for purposes of determining payments shall be calculated by multiplying the Net Sales of the Combination Products by the following formula: one (1) minus C/(C + D) where C is the
average selling price 
  

	[*]
	 
	Confidential treatment requested; certain information omitted and filed separately with the SEC. 
 

 
 5 

 
of the other product(s) and D is the difference between the average selling price of the Combination Products and the average selling price of the other product(s). Where neither the average sale
price of the Product nor the average sale price of the other products in the Combination Product can be determined, Net Sales for purposes of determining payments shall be (a) the Net Sales received for Combination Products (b) multiplied by a
fraction wherein the numerator is the fully burdened cost for the Product and the denominator is the fully burdened cost for the Combination Product. The Net Sales price for a Combination Product shall be calculated at the beginning of each calendar
year, and such price shall be used during all applicable reporting periods for that calendar year. When determining the average sale price of a Product, the average sale price shall be calculated using data arising from the twelve (12) months (or
such lesser number of months for which there may be sales data) preceding the calculation of the Net Sales price for the Combination Product. 
  
 (g)  If provision is made in law or regulation for withholding of taxes of any type, levies or other charges with respect to any amounts due and payable under this Agreement by VESTA to ICT,
VESTA shall be entitled to deduct such tax, levy or charge from the payment to be made by VESTA and pay such tax, levy or charge to the proper taxing authority. A receipt of payment of the tax, levy or charge secured shall be promptly delivered to
ICT, together with copies of all pertinent communications from or with such governmental authorities with respect thereto. At ICT’s reasonable request and at ICT’s expense, VESTA shall reasonably assist ICT in any effort by ICT in claiming
any exemption from such deductions or withholdings under any double taxation or similar agreement or treaty from time to time in force, and in minimizing the amount required to be so withheld or deducted. 
  
 (h)  All payments made to ICT hereunder shall be accompanied by a written statement setting forth in reasonable detail the
calculation thereof. VESTA shall maintain complete and accurate records sufficient to enable accurate calculation of payments due ICT hereunder. VESTA shall preserve such records and books of account for a period of three (3) years after the end of
the period covered by such records and books of account, which obligation shall survive expiration or termination of this Agreement. 
  
 (i)  VESTA shall permit an independent public accountant designated by ICT and reasonably acceptable to VESTA, to have access, no more than once in each calendar year during the term of this Agreement and no more
than twice during the three (3) calendar years following the expiration or termination of VESTA’s payment obligations hereunder, during regular business hours and upon at least ten (10) days prior written notice, to VESTA’s records and
books relating to amounts payable hereunder, for the purpose of determining the accuracy of Net Sales reported, and payments made, by VESTA to ICT within the one (1) year period immediately preceding such an audit. The independent public accountant
shall be under a confidentiality obligation to VESTA to disclose to ICT only (a) the accuracy of Net Sales reported and the basis for payments made to ICT under this Agreement, and (b) the difference, if any, by which such reported and paid amounts
vary from amounts determined as a result of the audit. The audit shall be at ICT’s expense. ICT will be under a continuing obligation of confidentiality to VESTA with respect to all information reported or generated during the audit. If such
examination results in a determination that Net Sales or payments have been understated or overstated, such determination shall be subject to review by an additional independent public accountant, designated by VESTA and reasonably acceptable to
ICT. In the event that such additional review confirms the existence and amount of any understatement or overstatement of 

 
 6 

 Net Sales or payments, as determined by the accountants retained by ICT, the unpaid amounts due shall be paid promptly by VESTA or the
overpayment amount shall be refunded promptly by ICT. In the event of an understatement of Net Sales or payments by five percent (5%) or more, VESTA shall reimburse ICT for the cost of the examination. In the event that such additional review
reaches a different determination than the determination reached by the accountants retained by ICT, as to the existence and/or amount of any understatement or overstatement of Net Sales or payments, the Parties shall negotiate in good faith to
resolve such differences. 
  
 SECTION 2.5  Legal Tender.    All
payments required to made under this Agreement shall be made in lawful money of the United States of America. 
  
  
 ARTICLE III—EXECUTION, CLOSING AND EFFECTIVENESS 
  
 SECTION 3.1  Execution; Closing; Deliveries. 
  
 (a)  The
transactions contemplated by this Agreement shall be consummated at a closing (the “Closing”) to occur on or before October 31, 2002, at VESTA’s offices in Bethesda, Maryland or at such other time or location as the parties may
mutually agree. 
  
 (b)  On or before the Closing Date, ICT shall deliver to VESTA, by hand delivery at the
Closing or by shipping such items to a destination in the United States specified by VESTA: (i) all tangible portions of the Acquired Assets (including, without limitation, the Documentation, the Regulatory Documentation and the Contracts), except
that the Inventory shall remain at its current location(s) ; and (ii) the Technical Package. 
  
 (c)  At
the Closing, ICT shall execute and deliver to VESTA a Bill of Sale and Assignment and Assumption Agreement substantially in the form of Schedule A (the “Bill of Sale and Assignment”) selling, assigning, transferring and conveying
the Acquired Assets to VESTA. 
  
 (d)  At the Closing, ICT shall deliver a certificate of its Chief
Executive Officer certifying: (i) that the conditions set forth in Sections 3.2(b)(ii), 3.2(b)(iii) and, if the Closing Date is after the date hereof, 3.2(b)(i) have been satisfied; (ii) that the corporate resolutions authorizing the execution,
delivery and performance of the ICT Agreements (as defined in Section 4.1(b)) the consummation of the transactions contemplated therein, attached thereto are in full force and effect and have not been amended, modified or rescinded; and (iii) as to
the incumbency and authority of the officers of ICT executing the ICT Agreements and acting on its behalf in connection with the transactions contemplated thereby. 
  
 (e)  At the Closing, ICT shall deliver to VESTA evidence that all Specified Consents have been obtained. 

 
 7 

  
 (f)  At the Closing, ICT shall cause its counsel to deliver to VESTA
certain legal opinions relating to corporate matters, dated the Closing Date, in the form of Schedule B. 
  
 (g)  At the Closing, VESTA shall make the payment to ICT as described in Section 2.3(a)(i). 
  
 (h)  At the Closing, VESTA shall deliver a certificate of its Chief Executive Officer certifying: (i) that the conditions set forth in Sections 3.2(a)(ii) and, if the Closing Date is after the date hereof, 3.2(a)(i) have
been satisfied; (ii) that the corporate resolutions authorizing the execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated herein, attached thereto are in full force and effect and have not been
amended, modified or rescinded; and (iii) as to the incumbency and authority of the officers of VESTA executing this Agreement and acting on its behalf in connection with the transactions contemplated hereby. 
  
 (i)  At the Closing Date, VESTA shall cause its counsel to deliver to ICT certain legal opinions relating to corporate matters,
dated the Closing Date, in the form of Schedule C. 
  
 SECTION 3.2  Conditions
Precedent to Closing. 
  
 (a)  Conditions Precedent to Obligations of
ICT.    The obligation of ICT to consummate the transactions contemplated by this Agreement to be consummated at the Closing shall be subject to the reasonable satisfaction, or to the waiver by ICT in writing, on or before
the Closing Date, of the following conditions, all of which are for the sole benefit of ICT: 
  
 (i)  all representations and warranties of VESTA set forth in Article V or elsewhere in this Agreement shall have been true, correct and complete when made and shall be true, correct and complete as of the Closing Date;

  
 (ii)  VESTA shall have performed and complied in all material respects with each and
every covenant, agreement and condition required by this Agreement to be performed or complied with by VESTA prior to or on the Closing Date; 
  
 all actions required to be taken, and deliveries required to be made or caused to be made, by VESTA at Closing pursuant to Section 3.1 shall have been taken or made;and, 
  
 (iv)  the Board of Directors of VESTA shall have unanimously approved this Agreement. 
  
 (b)  Conditions Precedent to Obligations of VESTA.    The obligation of VESTA to consummate the
transactions contemplated by this Agreement to be consummated at the Closing shall be subject to the reasonable satisfaction, or to the waiver by VESTA in writing, on or before the Closing Date, of the following conditions, all of which are for the
sole benefit of VESTA: 
  
 (i)  all representations and warranties of ICT set forth in
Article IV or elsewhere in this Agreement shall have been true, correct and complete when made and shall be 

 
 8 

 
true, correct and complete as of the Closing Date and any exceptions set forth in the Schedules shall be acceptable to VESTA, in VESTA’s sole discretion; 
  
 (ii)  ICT shall have performed and complied in all material respects with each and every covenant, agreement and
condition required by this Agreement to be performed or complied with by ICT prior to or on the Closing Date; 
  
 (iii)  all Specified Consents shall have been obtained on terms satisfactory to VESTA, including without limitation, the modification of the terms of the Transamerica Note; 
  
 (iv)  all actions required to be taken, and deliveries required to be made or caused to be made, by ICT at
Closing pursuant to Section 3.1 shall have been taken or made; 
  
 (v)  the Board of
Directors of ICT shall have unanimously approved this Agreement;, 
  
 (vi)  all contracts,
agreements, obligations and any other promises of or by ICT relating to or affecting the Acquired Assets, whether contingent or fixed, have been satisfied or terminated by ICT. To the extent said obligations are solely financial obligations, are
fully disclosed in Schedule 4.8, and ICT has arranged for VESTA to pay such obligations directly out of the payment under 2.3(a)(i), then to such extent the satisfaction of these financial obligations by VESTA shall not be a condition to Closing;
and, 
  
 (vii)  all contracts, agreements, obligations and any other promises of or by ICT
not relating to or affecting the Acquired Assets, whether contingent or fixed, will have been satisfied or terminated by ICT within ten (10) days of the Closing Date. 
  
 SECTION 3.3  Further Assurances.    From time to time within two (2) years after the Closing Date, ICT shall, at
VESTA’s expense, execute and deliver any further instruments or documents as VESTA may reasonably request in order to accomplish transfer of the Acquired Assets to VESTA as contemplated hereby. 
  
 SECTION 3.4  No Brokers.    ICT and VESTA mutually represent and warrant to each other
that they have not negotiated with any broker or finder in connection with this Agreement or the subject matter hereof. Each party agrees that should any claim be made against the other party for any broker’s commission or finder’s fee by
reason of the acts of such party, the party upon whose acts such claim is adjudicated shall hold the other party harmless from and against all liability and expense in connection therewith. 
  

 
 ARTICLE IV—ICT’S REPRESENTATIONS AND WARRANTIES 
  
 ICT represents and warrants as of the date hereof and as of the Closing Date that: 
  
 SECTION 4.1  Corporate Existence and Authorization; No Contravention; Specified Consents. 

 
 9 

  
 (a)  ICT is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware. ICT has the requisite corporate power and authority to own, lease, license and sell the Acquired Assets. 
  
 (b)  ICT has the requisite corporate power and authority to execute and deliver this Agreement and the related Bill of Sale and Assignment (collectively, the “ICT Agreements”) and
to perform the transactions contemplated hereby and thereby. The execution, delivery and performance of each of the ICT Agreements has been duly and validly authorized by all necessary corporate and stockholder action on the part of ICT. Each ICT
Agreement has been, or will be at the Closing, duly executed and delivered by ICT and each constitutes, or will constitute when executed and delivered, a valid and binding obligation of ICT, enforceable against ICT in accordance with its
terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the rights and remedies of creditors, and subject to the further qualification that the remedy of specific performance or injunctive relief is
discretionary with the court before which any proceeding therefor may be brought. 
  
 (c)  The execution,
delivery and performance by ICT of the ICT Agreements do not and will not: 
  
 (i)  conflict with or constitute a violation of the Certificate of Incorporation or Bylaws of ICT; 
  
 (ii)  conflict with or constitute a violation of any law, statute, judgment, order, decree or regulation of any legislative body, court, administrative agency, governmental authority or
arbitrator applicable to or relating to ICT or the Acquired Assets; 
  
 (iii)  conflict
with, constitute a default under, result in a breach or acceleration of or, except as set forth on Schedule 4.1, require notice to or the consent of any third party under any contract, agreement, commitment, lease, mortgage, note, license or
other instrument or obligation to which ICT is party or by which it is bound or by which the Acquired Assets are affected; or 
  
 (iv)  result in the creation or imposition of any Lien or encumbrance of any nature whatsoever on any of the Acquired Assets. 
  
 (d)  Schedule 4.1 sets forth the Specified Consents, to include the Required Notice, in substantially the form attached hereto as Schedule D.

  
 SECTION 4.2  Status of Acquired Assets. 
  
 (a)  ICT has good and marketable title to all of the Acquired Assets, free and clear of any Liens. 
  
 (b)  To ICT’s best knowledge, no product, formula, formulation, trademark, process, method, substance, or other material
that is part of the Acquired Assets infringes any rights owned or held by any Person, and, to the best knowledge of ICT, no item currently being 

 
 10 

  
 manufactured, distributed, sold or used by any Person infringes any rights of ICT to the Acquired
Assets. 
  
 SECTION 4.3  Financial Statement.    ICT has
previously delivered to VESTA a true and complete copy of its unaudited statement of operations relating to ICT’s operating revenues and expenses for the eleven (11) months ended August 31, 2002 (the “Financial Statement”). The
Financial Statement: (a) is true, correct and complete; (b) is in accordance with the books and records of ICT; and (c) presents fairly ICT’s results of operations for the period shown. 
  
 SECTION 4.4  Litigation.    There are no claims, actions, suits, arbitration proceedings, inquiries, hearings,
injunctions or investigations (“Claims”) pending, or to the knowledge of ICT, threatened, against ICT relating to the Product or any of the Acquired Assets. No Claims have been brought within the last two (2) years against ICT relating to
a Product or any of the Acquired Assets. To ICT’s knowledge, there are no facts or circumstances which could serve as the basis for any Claim against ICT involving the Product or any of the Acquired Assets, or, by virtue of the
execution, delivery and performance of this Agreement, against VESTA. 
  
 SECTION
4.5  Compliance with Laws.    There is not outstanding or, to the knowledge of ICT, threatened any order, writ, injunction or decree of any court, governmental agency or arbitration tribunal against or involving
the Product or the Acquired Assets. ICT is currently in full compliance with all laws, statutes, rules, regulations, orders and licensing requirements (“Rules”) of federal, state, local and foreign agencies and authorities applicable to
the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of the Product or any of the Acquired Assets. To the knowledge of ICT, there has been no allegation of any violation
of any such Rules, and no investigation or review by any federal, state or local body or agency is pending, threatened or planned with respect to the Product or any of the Acquired Assets. 
  
 SECTION 4.6  Utilization of Acquired Assets.    The Acquired Assets constitute all of the assets, tangible and
intangible, of any nature whatsoever, currently used by ICT in connection with the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of the Product. 

 
 SECTION 4.7  Inventory.    Except as otherwise described on
Schedule 4.7, all items included in the Inventory are: (i) in good condition and not obsolete or defective; and (ii) useable or saleable in the ordinary course of business consistent with ICT’s
past practice, subject to normal wear and maintenance. All of the Inventory is described, and the location of all such Inventory is set forth, on Schedule 4.7. 
  
 SECTION 4.8  Contracts.    All of the Contracts that (i) are not terminable by either party without penalty on 30 days
notice or (ii) are material to the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of the Product by ICT are listed on Schedule 4.8. ICT has delivered to VESTA
true and complete copies of all written Contracts, including any and all amendments and other modifications thereto. Each of the Contracts is valid, binding and enforceable in accordance with its terms and is in full force and effect. ICT has not
waived any of its rights under, or modified the terms of, any Contract orally or by a pattern of practice or otherwise. 

 
 11 

  
 There are no existing defaults except as disclosed on Schedule 4.8 and as expressly agreed to be paid by
VESTA under Section 3.2(b)(vi), and no events or circumstances have occurred which, with or without notice or lapse of time or both, would constitute defaults, under any of the Contracts. The assignment of the Contracts by ICT to VESTA will not,
with respect to any Contract: (i) constitute a default thereunder; (ii) require the consent of any person or party, except for the Specified Consents; or (iii) affect the continuation, validity and effectiveness thereof or the terms thereof.

  
 SECTION 4.9  Suppliers and Customers.    Each supplier of
goods or services to ICT in respect of the Product to which ICT paid more than $25,000 during the twelve (12) months ended on September 30, 2002, and each customer of ICT in respect of cell processing revenue who paid ICT any amount during such
period, are listed on Schedule 4.9 and Schedule 4.7, respectively, which Schedules reflect in each case the amounts so paid. ICT is not engaged in any dispute with any of such suppliers or customers. 
  
 SECTION 4.10  Clinical Trials.    ICT has provided VESTA with all information
concerning side effects, injury, toxicity or sensitivity reaction, or unexpected incidents, whether or not serious or unexpected, relating to the Product (“Adverse Experiences”).ICT’s IND BB-IND 10538 is, and has been, ICT’s sole
clinical trial. ICT has not enrolled patients in any clinical trial, including without limitation said IND BB-IND 10538, at any time. ICT has not been associated in any way with any other clinical trial, or patient treatment, of any kind.

  
 SECTION 4.11  Intellectual Property.    All items of
Intellectual Property are described in reasonable detail on Schedule 4.10. ICT has not disclosed any information included in the Acquired Assets to any third party, except to its advisors, attorneys and consultants and except pursuant to
confidentiality arrangements, including confidential treatment requests filed with the Securities and Exchange Commission (the “SEC”), and has taken reasonable measures to protect all such information as confidential. ICT (i) owns all
right, title and interest in and to, or (ii) has an exclusive license to or right to exclusively license, each item included in the Intellectual Property, free and clear of any Liens. Except as otherwise disclosed in Schedule 4.10, ICT has
not licensed any of the Intellectual Property to any third party, and to ICT’s knowledge no third party other than the licensors otherwise has any right to use any of the Intellectual Property and as to the licensors, said licensors retain only
the right to use the Intellectual Property in noncommercial research. There are no claims or suits against ICT challenging ICT’s ownership of or right to use any of the Intellectual Property, nor to ICT’s knowledge does there exist any
basis therefor. There are no claims or suits against ICT alleging that any of the Intellectual Property or any of ICT’s use of the Intellectual Property infringes any rights of any third parties, nor to ICT’s knowledge does there exist any
basis therefor. 
  
 SECTION 4.12  Tax Matters.    In all respects
relating to the Product or any of the Acquired Assets: (i) ICT has filed all federal, state, local and foreign tax returns required to be filed; (ii) each such return is complete, accurate and in compliance with applicable law and regulations in all
material respects; and (iii) ICT has paid or provided for all such taxes of any nature whatsoever, with any related penalties, interest and liabilities, that are or would be shown on such tax returns as due and payable on or before the date hereof,
other than such taxes as are being contested in good faith. 

 
 12 

  
 SECTION 4.13  Characteristics of
Product.    All Recorded Information in the possession of, or readily obtainable by, ICT reflecting quality, toxicity, safety and/or efficacy characteristics of the Product has been disclosed to VESTA in writing prior to the
date hereof or will be disclosed to VESTA on the Closing Date. 
  
 SECTION  4.14  Solvency.    As of the completion of this transaction, ICT will not be insolvent and will not be rendered insolvent by any of the transactions contemplated
by this Agreement. In addition, immediately after giving effect to the consummation of the transactions contemplated by this Agreement: (i) ICT will be able to pay its debts as they become due; and (ii) ICT will not have unreasonably small assets
with which to conduct its present or proposed business. As used in this Section, (i) “insolvent” means that the sum of the present fair saleable value of ICT’s assets does not and will not exceed its debts and other probable
liabilities; and (ii) “debts” includes any legal liability, whether matured or unmatured, liquidated or unliquidated, absolute, fixed or contingent, disputed or undisputed or secured or unsecured. 
  
 SECTION 4.15  Disclosure.    No representation, warranty or statement made by ICT in
any of the ICT Agreements, or any document furnished or to be furnished to VESTA pursuant to any of the ICT Agreements, contains or will contain any untrue statement of a material fact, or omits or will omit to state any material fact necessary to
make the statements contained herein or therein not misleading. As of the date this Agreement is executed and as of the Closing Date, ICT has made and will have made full disclosure of all material facts relating to the Acquired Assets, including
without limitation, all financial commitments, obligations or liabilities, contingent or otherwise, relating to or affecting the Acquired Assets. 
  
 SECTION 4.16  Trademarks.    ICT has filed no trademark application(s) and has no rights to or in any trademarks or trademark applications.

  
 ARTICLE V—VESTA’S REPRESENTATIONS AND WARRANTIES 
  

VESTA represents and warrants as of the date hereof and as of the Closing Date that: 
  
 SECTION 5.1  Corporate Existence.    VESTA is a corporation duly organized and validly existing under the laws of the
State of Delaware. 
  
 SECTION 5.2  Due Authorization; Binding
Agreement.    VESTA has the requisite corporate power and authority to execute, deliver and perform this Agreement and any related agreements to which VESTA is a party (collectively, the “VESTA Agreements”) and to
consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of the VESTA Agreements, and the consummation of the transactions contemplated hereby and thereby, have been duly and validly authorized by all
necessary corporate action on the part of VESTA. The VESTA Agreements have been or, with respect to VESTA Agreements to be executed at the Closing, will be duly executed and delivered by VESTA and each constitutes or will constitute when executed
and delivered a valid and binding obligation of VESTA, enforceable against VESTA in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the rights and remedies of creditors, and subject
to the further qualification that the remedy of specific performance or 

 
 13 

 
injunctive relief is discretionary with the court before which any proceeding therefor may be brought. 
  
 SECTION 5.3  No Contravention.    The execution, delivery and performance of the VESTA Agreements do not and will not: (i) conflict with or
constitute a violation of the Certificate of Incorporation or Bylaws of VESTA; or (ii) conflict with or constitute a violation of any law, statute, judgment, order, decree or regulation of any legislative body, court, administrative agency,
governmental authority or arbitrator applicable to or relating to VESTA. 
  
 SECTION
5.4  No Government Action.    To VESTA’s knowledge, except for the requirement that both VESTA and ICT provide written notice, in the form attached hereto as Schedule D, of the transfer of the
Regulatory Documentation from ICT to VESTA, the execution, delivery and performance by VESTA of this Agreement and each of the documents contemplated hereby to which VESTA is a party require no action by or in respect of, or filing with, any
governmental body, agency or official. 
  
 SECTION
5.5  Disclosure.    No representation, warranty or statement made by VESTA in this Agreement, or any document furnished or to be furnished to ICT pursuant to this Agreement, contains or will contain any untrue
statement of a material fact, or omits or will omit to state any material fact necessary to make the statements contained herein or therein not misleading. 
  
  

ARTICLE VI—ICT’S COVENANTS 
  
 ICT covenants and agrees as follows: 
  
 SECTION
6.1  Filings.    ICT will use commercially reasonable efforts in good faith to file or cause to be filed with the FDA, as soon as practicable after the Closing Date, the Required Notice (substantially in the form
attached hereto as Schedule D). 
  
 SECTION 6.2  No Liens; Full
Payment.    Any Liens with respect to any of the Acquired Assets shall be satisfied of record on or prior to the Closing Date by ICT. All contracts, agreements, obligations and any other promises of or by ICT, whether
contingent or fixed, will have been satisfied and paid in full by ICT not later than ten (10) days of the Closing Date. 
  
 SECTION 6.3  Confidentiality.    Until five years following the Closing Date, ICT will, and will cause each of its employees to, use commercially reasonable efforts to preserve the
confidentiality of all confidential and proprietary information used in connection with the research, development, manufacture, production, sales, marketing, distribution, license, exploitation and/or commercialization of the Product or any of the
Acquired Assets (the “Product Information”), provided that ICT may use and disclose any such information which has been publicly disclosed (other than by ICT in breach of its obligations under this Agreement) or to the extent that ICT may
become legally compelled to disclose any of such information, in which case ICT shall, prior to disclosure, first use commercially reasonable efforts in good faith, and afford VESTA the opportunity, to obtain an appropriate protective order, or
other satisfactory assurance of confidential treatment, for the information required to be so disclosed. 

 
 14 

  
 SECTION 6.4  Removal of Information from
Website.    Not later than the business day after the Closing Date, ICT shall delete to the extent permitted by law from any and all of its websites (including, without limitation, incara.com) all references to, any and all
information pertaining to, the Product and the Acquired Assets, except for references contained in filings made by Incara Pharmaceuticals Corporation with the SEC and press releases issued by ICT or its Affiliates prior to the Closing Date. To the
extent required by law press releases must be retained on the website, then ICT shall post a prominent notice disclosing the sale of the Acquired Assets to VESTA. Notwithstanding the foregoing, announcements and disclosures agreed to under Section
9.7 shall be permitted. 
  
 SECTION 6.5  Non-Competition.    ICT
hereby agrees that, for two years after the Closing Date, ICT will not, directly or indirectly, and will not establish any Affiliate to, conduct any business involving Cell Therapy. For the avoidance of doubt, nothing contained in this Section 6.5
is intended to grant to ICT a license to, or to permit the infringement of, any intellectual property of VESTA. 
  
 SECTION 6.6  Standstill.    ICT will neither enter into nor commit to any agreements relating to or affecting any of the Acquired Assets, including but not limited to the
Intellectual Property, prior to the Closing Date. ICT and VESTA will each work in good faith, to complete the purchase and sale of the Acquired Assets in accordance with the terms of this Agreement. ICT will use best efforts to consummate the
closing by the Closing Date. 
  
 SECTION 6.7  Technology
Transfer.    To the extent reasonably necessary to effectuate the full and complete transfer of technology, including but not limited to the transfer of the Intellectual Property, Know-How and Technical Package, to VESTA, ICT
will provide reasonable technology transfer assistance at no charge to VESTA during the period up to twelve months after the Closing Date. For the period from twelve months after the Closing Date to eighteen months after the Closing Date, ICT will
provide reasonable technology transfer assistance at reasonable cost. 
  
  
 ARTICLE
VII—VESTA’S COVENANTS 
  
 VESTA covenants and agrees as follows: 
  
 SECTION 7.1  FDA Filings.    VESTA will use commercially reasonable efforts in good
faith promptly to file or cause to be filed with the FDA, any notice, document and/or other materials required to be filed by it in connection with its purchase of the Acquired Assets (including, without limitation, the filings required by 21 CFR
Section 314.72) and to make promptly any further filings and take any actions required of it as may be necessary to consummate the transactions contemplated hereby. 
  
 SECTION 7.2  Cooperation in Litigation.    From and after the Closing Date, VESTA agrees that, in the defense by ICT of
any litigation, hearing, regulatory proceeding or investigation or other similar matter relating to the Acquired Assets or the Assumed Liabilities, VESTA will make available to ICT at ICT’s expense during normal business hours, but without
unreasonably disrupting its business, all records as to the Acquired Assets and Assumed 

 
 15 

 
Liabilities held by VESTA and reasonably necessary to permit the effective defense or investigation of such matters. 
  
  
 ARTICLE VIII—SURVIVAL; INDEMNIFICATION 
  
 SECTION 8.1  Survival.    All representations and warranties of the parties contained herein shall survive the Closing Date until one (1) year after
the Closing Date. The covenants and agreements of ICT and VESTA hereunder that require by their express terms performance or compliance on and after the Closing Date shall continue in force thereafter in accordance with their terms. 

 
 SECTION 8.2  Indemnification by ICT.    ICT shall indemnify, defend and
hold harmless VESTA and its officers, directors and affiliates (collectively, the “VESTA Indemnitees”) from, against and with respect to any action or cause of action, loss, damage, claim, obligation, liability, penalty, fine, cost and
expense (including, without limitation, reasonable attorneys’ and consultants’ fees and costs and expenses incurred in investigating, preparing, defending against or prosecuting any litigation, claim, proceeding, demand or request for
action by any governmental or administrative entity), of any kind or character, but expressly excluding all foreseeable and unforeseeable consequential damages (a “Loss”): (i) arising out of or in connection with any breach of any of the
representations or warranties of ICT contained in this Agreement; (ii) arising out of or in connection with any failure by ICT to perform or observe any covenant, agreement, obligation or condition to be performed or observed by it pursuant to this
Agreement; or (iii) constituting an Excluded Liability. Notwithstanding anything to the contrary, this Section 8.2 shall expire one (1) year after the Closing Date of the Agreement. 
  
 SECTION 8.3  Indemnification by VESTA.    VESTA shall indemnify, defend and hold harmless ICT and its officers,
directors and affiliates (collectively, the “ICT Indemnitees”) from, against and with respect to any Loss: (i) arising out of or in connection with any breach of any of the representations or warranties of VESTA contained in this
Agreement; (ii) arising out of or in connection with any failure by VESTA to perform or observe any covenant, agreement, obligation or condition to be performed or observed by it pursuant to this Agreement; or, (iii) constituting an Assumed
Liability. Notwithstanding anything to the contrary, this Section 8.3 shall expire one (1) year after the Closing Date of the Agreement. 
  
 SECTION 8.4  Indemnification; Notice and Settlements.    A party seeking indemnification pursuant to Section 8.2 or 8.3 (an “indemnified party”) shall give prompt
notice to the party from whom such indemnification is sought (the “indemnifying party”) in writing of any claim for recovery, specifying in reasonable detail the nature of the Loss. The indemnified party shall provide to the indemnifying
party as promptly as practicable thereafter all information and documentation reasonably requested by the indemnifying party to verify the claim asserted; provided that, in the event of a third party claim giving rise to the Loss, the failure of the
indemnified party to notify the indemnifying party on a timely basis will not relieve the indemnifying party of any liability that it may have to the indemnified party, except to the extent that the indemnified party demonstrates that the defense of
such action is materially prejudiced by the indemnifying party’s failure to give such notice. The indemnifying party shall have the right to, and shall at the request of the indemnified party, assume the defense, with counsel reasonably
satisfactory to the indemnified party, of any such suit, action or proceeding at its own 

 
 16 

  
 expense. An indemnifying party shall not be liable under Section 8.2 or 8.3 for any settlement effected
without its consent of any claim, litigation or proceeding in respect of which indemnity may be sought hereunder, which consent shall not be unreasonably withheld. 
  
 SECTION 8.5  Other Remedies.    The foregoing indemnification provisions are in addition to, and not in derogation of,
any statutory, equitable or common law remedy any party may have as a result of a Loss. 
  
 ARTICLE IX—MISCELLANEOUS

  
 SECTION 9.1  Notices.    All notices, demands and other
communications made hereunder shall be in writing and shall be given either by personal delivery or by nationally recognized overnight courier (with charges prepaid) and shall be deemed to have been given or made when actually delivered.

  
 if to ICT to: 
 Incara Cell Technologies, Inc. 
 79 T. W. Alexander Drive 
 4401 Research Commons, Suite 200 
 Research
Triangle Park, NC 27709 
 Attention: Clayton I. Duncan 
  
 with a copy to: 
 Wyrick Robbins Yates &
Ponton LLP 
 4101 Lake Boone Trail, Suite 300 
 Raleigh, NC 27607 
 Attention: Larry E. Robbins 
  
 If to VESTA to: 
 Vesta Therapeutics, Inc.

 7600 Wisconsin Avenue 
 Bethesda, MD 20814 
 Attention: Alan Smith, Ph.D. 
  
 with a copy to: 
 Toucan Capital Corp.

 7600 Wisconsin Avenue 
 Bethesda, MD 20814 
 Attention: Linda Powers 

 
 17 

  
 SECTION 9.2  Expenses.    All
legal and other costs and expenses incurred in connection herewith and the transactions contemplated hereby shall be paid by the party incurring such expenses. 
  
 SECTION 9.3  Limitation on ICT’s Representations and Warranties.    VESTA ACKNOWLEDGES THAT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES OF
ICT CONTAINED IN THIS AGREEMENT, VESTA IS ACQUIRING THE ACQUIRED ASSETS ON AN “AS IS, WHERE IS” BASIS WITHOUT ANY EXPRESS OR IMPLIED WARRANTIES AS TO THE FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY. 
  
 SECTION 9.4  Successors and Assigns.    This Agreement shall be binding upon and shall
inure to the benefit of the parties and their respective successors and assigns; provided, however, that this Agreement may not be assigned by either party without the prior written consent of the other party hereto and any attempted assignment
without such consent shall be void. 
  
 SECTION 9.5  Entire Agreement;
Amendment.    This Agreement, including without limitation the Schedules hereto, embodies the entire agreement of the parties hereto with respect to the subject matter hereof and supersedes any and all prior agreements with
respect thereto, except for any prior confidentiality agreements which shall survive. In the event of any conflict between this Agreement and any such prior confidentiality agreement, the agreement imposing stricter confidentiality shall govern. No
waiver, amendment or modification of any provision hereof or of any right or remedy hereunder shall be effective unless in writing and signed by the party against whom such waiver, amendment or modification is sought to be enforced. 

 
 SECTION 9.6  Captions; Construction.    Captions herein are inserted for
convenience of reference only and shall be ignored in the construction or interpretation of this Agreement. Unless otherwise specified, the words “herein,” “hereof” and terms of like import shall be deemed to refer to the
Agreement as a whole and not merely to a single part thereof. 
  
 SECTION 9.7  Public
Announcement.    Each of ICT and VESTA agrees it will not make any press releases or other public announcements with respect to the transactions contemplated hereby, except as required by applicable law, without the prior
approval of the other party not to be unreasonably withheld. 
  
 SECTION
9.8  Efforts.    Each party agrees to use commercially reasonable efforts to satisfy the conditions to the Closing set forth in this Agreement and otherwise to consummate the transactions contemplated by this
Agreement. 
  
 SECTION 9.9  Governing Law.    This Agreement
shall be governed by, interpreted and construed, and all claims and disputes, whether in tort, contract or otherwise shall be resolved, in accordance with the substantive laws of the Commonwealth of Delaware, without regard to the principles of
conflicts of laws. 
  
 SECTION 9.10  Waiver.    No waiver by any
party in one or more instances of any of the provisions of this Agreement or the breach thereof shall establish a precedent for any other 

 
 18 

 instance with respect to that or any other provision. Furthermore, in case of waiver of a particular provision, all other provisions of this
Agreement will continue in full force and effect. 
  
 SECTION
9.11  Severability.    If any provision of this Agreement is held to be invalid or unenforceable, all other provisions shall nevertheless continue in full force and effect. 
  
 SECTION 9.12  Counterparts.    This Agreement may be executed in two counterparts,
each of which shall be deemed to be an original and both of which, taken together, shall constitute but one and the same instrument. 
  
 SECTION 9.13  No Third Party Beneficiaries.    Except for the rights of the “VESTA Indemnitees” and the “ICT Indemnitees” under Article VIII, none of
the provisions of this Agreement or any document contemplated hereby is intended to grant any right or benefit to any person or entity that is not a party to this Agreement. 
  
 SECTION 9.14  Specific Performance.    ICT agrees that after VESTA has paid the Three Million Dollar ($3,000,000)
purchase price, if ICT fails to make the Required Notice, then VESTA shall be entitled, in addition to its other remedies at law or at equity, to specific performance of this Agreement to the extent of the Required Notice. 
  
 [remainder of page intentionally left blank] 

 
 19 

  
 IN WITNESS WHEREOF, this Agreement has been signed by authorized representatives
on behalf of each of the parties hereto as of the day and year first above written. 
  
 
	 VESTA THEAPEUTICS, INC. 
 
	 
	 By:
 	 	 /s/    ANNEMARIE
MOSELEY        
 

	  	 	 Annemarie Moseley
 Acting
CEO
 

 
  
 
	 INCARA CELL TECHNOLOGIES, INC.
 
	 
	 By:
 	 	 /s/    CLAYTON I.
DUNCAN        
 

	  	 	 Clayton I. Duncan
 President
& CEO
 

 

 
 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]